Page last updated: 2024-11-04

sorbic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Sorbic Acid: Mold and yeast inhibitor. Used as a fungistatic agent for foods, especially cheeses. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(2E,4E)-hexa-2,4-dienoic acid : A sorbic acid having trans-double bonds at positions 2 and 4; a food preservative that can induce cutaneous vasodilation and stinging upon topical application to humans. It is the most thermodynamically stable of the four possible geometric isomers possible, as well as the one with the highest antimicrobial activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

sorbic acid : A hexadienoic acid with double bonds at C-2 and C-4; it has four geometrical isomers, of which the trans,trans-form is naturally occurring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID643460
CHEMBL ID250212
CHEBI ID38358
CHEBI ID35962
SCHEMBL ID1647
MeSH IDM0020168

Synonyms (152)

Synonym
MLS002152937
smr001224532
AN-651/40229308
sorbic acid
nsc-49103
2,4-hexadienoic acid
nsc-50268
nsc-35405
2,4-sa
(2-butenylidene) acetic acid
CHEBI:38358 ,
2,4-hexadiensaeure
trans,trans-sa
22500-92-1
sorbinsaeure
(e,e)-sorbic acid
(2e,4e)-2,4-hexadienoic acid
(e,e)-sa
CHEBI:35962 ,
(e,e)-1,3-pentadiene-1-carboxylic acid
einecs 203-768-7
1,3-pentadiene-1-carboxylic acid, (e,e)-
hsdb 590
caswell no. 801
acetic acid, crotylidene-
kyselina sorbova [czech]
ccris 5748
acetic acid, (2-butenylidene)-
kyselina 1,3-pentadien-1-karboxylova [czech]
ai3-14851
trans-trans-2,4-hexadienoic acid
(e,e)-sorbic acid; sorbic acid
sorbic acid [usan]
epa pesticide chemical code 075901
e 200
2,4-hexadienoic acid, (e,e)-
110-44-1
(2e,4e)-hexa-2,4-dienoic acid
D05892
sorbic acid (nf)
hexadienoic acid, (e,e)
inchi=1/c6h8o2/c1-2-3-4-5-6(7)8/h2-5h,1h3,(h,7,8)/b3-2+,5-4
2-propenylacrylic acid
preservastat
(2-butenylidene)acetic acid
2,4-hexadienoic acid, (2e,4e)-
sorbistat
(e,e)-2,4-hexadienoic acid
crotylidene acetic acid
trans,trans-2,4-hexadienoic acid
hexadienoic acid
panosorb
alpha-trans-gamma-trans-sorbic acid
trans,trans-sorbic acid
1,3-pentadiene-1-carboxylic acid
NCGC00091737-01
2,4-hexadienoic acid, >=99%, fcc
sorbic acid, >=99.0%
sorbic acid, analytical standard
LMFA01030100
2e,4e-hexadienoic acid
c6:2n-2,4
fema no. 3921
ins-200
CHEMBL250212
e200
sorbic acid, (e,e)-
S0053
AKOS000119456
NCGC00091737-02
NCGC00091737-03
HMS3039E13
tox21_201719
tox21_300182
NCGC00259268-01
NCGC00253957-01
A829400
cas-110-44-1
dtxsid3021277 ,
tox21_111164
dtxcid401277
acid, propenylacrylic
acid, sorbic
acid, hexadienoic
sorbic acid [nf]
kyselina 1,3-pentadien-1-karboxylova
x045wj989b ,
kyselina sorbova
ec 203-768-7
unii-x045wj989b
S4983
c6h8o2
sorbic acid [ep monograph]
sorbic acid [fcc]
sorbic acid [usp-rs]
sorbic acid [ii]
(e,e)-2,4-hexadienoic acid [fhfi]
sorbic acid [mart.]
sorbic acid [inci]
sorbic acid [who-dd]
sorbic acid [hsdb]
sorbic acid [vandf]
sorbic acid [mi]
.alpha.-trans-.gamma.-trans-sorbic acid
SCHEMBL1647
(e,e)-hexa-2,4-dienoic acid
e-sorbic acid
hexa-2,4-dienoic acid, (e,e)-
2,4-hexadienoic acid, (trans,trans)-
(2e,4e)-2,4-hexadienoic acid #
F8886-8255
acidum sorbicum
mfcd00002703
J-524281
J-002425
sorbic acid, tested according to ph.eur.
sorbic acid, saj first grade, >=98.5%
sorbic acid, united states pharmacopeia (usp) reference standard
sorbic acid, vetec(tm) reagent grade, 98%
sorbic acid, pharmaceutical secondary standard; certified reference material
sorbic acid, european pharmacopoeia (ep) reference standard
sorbic acid, for synthesis, 99.0-101.0%
sorbinsaure
Z57127888
crotylidene-acetic acid
sorbic acid, potassium salt (van)
fema 3921
2, 4-hexadienoic acid potassium salt
hexadienoic acid1,3-pentadiene-1-carboxylic acid
(2-butenylidene)-acetic acid
alpha-trans-laquo gammaraquo -trans-sorbic acid
Q407131
HY-N0626
hexadienic acid
sorbic acid 1000 microg/ml in acetonitrile
STR09707
(2e,4e)-2,4-hexenoic acid
sorbic-acid
CCG-266056
NCGC00091737-05
CS-0009618
EN300-332923
EN300-17945
E80726
HB8334
sorbic acid (sa)
STARBLD0040592
sorbic acid (ii)
sorbic acid (ep monograph)
sorbic acid (mart.)
sorbic acid (usp-rs)
trans, trans-sorbic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Thus, sorbic acid and its potassium salt at the concentrations used for food preservation can still be considered as safe for human consumption."( The potential genotoxicity of sorbates: effects on cell cycle in vitro in V79 cells and somatic mutations in Drosophila.
Graf, U; Holliger, E; Kränzlin, R; Maier, P; Schlatter, J; Würgler, FE, 1992
)
0.28
"Butylparaben sodium (BP), sodium diacetate (SDA) and potassium sorbate (PS) are safe and internationally recognized preservatives."( Comparative toxic effects of butylparaben sodium, sodium diacetate and potassium sorbate to Dunaliella tertiolecta and HL7702 cells.
Chen, HH; Jiang, JG; Shang, Y; Xu, XL, 2017
)
0.46
" Overall, it can be concluded that the aforementioned food additives can be used as safe additives at low concentration in food industry."( Safety assessment of sodium acetate, sodium diacetate and potassium sorbate food additives.
Dehghan, P; Ezzati Nazhad Dolatabadi, J; Mohammadi, A; Mohammadzadeh-Aghdash, H; Shanehbandi, D; Sohrabi, Y, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
"A physiologically based pharmacokinetic (PBPK) model was developed to describe the disposition of benzene in 3- and 18-month C57BL/6N mice and to examine the relevant physiologic and/or biochemical parameters governing previously observed age-related changes in the disposition of benzene."( Age-related changes in benzene disposition in male C57BL/6N mice described by a physiologically based pharmacokinetic model.
Birnbaum, LS; McMahon, TF; Medinsky, MA, 1994
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
" After the required regulatory approval, treatment of whole cantaloupe with nisin in combination with EDTA, NaL, KS, or NaL and KS and of fresh-cut pieces with nisin-NaL or NaL-KS could help ensure the microbiological safety of fresh-cut cantaloupe."( Effect of nisin in combination with EDTA, sodium lactate, and potassium sorbate for reducing Salmonella on whole and fresh-cut cantaloupet.
Fett, WF; Ukuku, DO, 2004
)
0.32
" Application of CH coating alone or in combination with potassium sorbate could decrease the CI symptoms and preserved peel cell membrane integrity by maintaining electrolyte leakage (EL) and malondialdehyde in lower levels."( Impact of chitosan in combination with potassium sorbate treatment on chilling injury and quality attributes of pomegranate fruit during cold storage.
Molaei, S; Rabiei, V; Razavi, F; Soleimani, A, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"The ocular bioavailability of timolol increased in sorbic acid solution due to ion pair formation."( Improvement of the ocular bioavailability of timolol by sorbic acid.
Higashiyama, M; Inada, K; Ohtori, A; Tojo, K, 2004
)
0.32
" In the present study, we desired to evaluate the ocular comfort and systemic bioavailability of TLA in healthy volunteers in comparison to standard timolol maleate ophthalmic solution (TIM)."( Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers.
Crockett, RS; Inui, N; Mundorf, TK; Naka, H; Novack, GD; Ogawa, T, 2005
)
0.33
" If a correlation existed between these data and in vivo DDAVP bioavailability after nasal administration, this could strengthen the safety concerns related to the use of this medication in adults and children."( In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: the enhancing effect of potassium sorbate.
Balducci, AG; Bortolotti, F; Colombo, G; Fabio, S; Fabrizio, B; Gaia, C; Giulia, BA; Paola, R; Russo, P; Sonvico, F, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Famotidine (FMT) an anti-ulcer drug, recently being repurposed in COVID-19 treatment, suffers from poor aqueous solubility and restricted bioavailability (<40%)."( Pharmaceutical Cocrystals of Famotidine: Structural and Biopharmaceutical Evaluation.
Chadha, K; Chadha, R; Dhingra, N; Dureja, J; Jindal, A; Karan, M; Prashar, M, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Monkeys were dosed ip with 5, 50, or 500 mg [14C]benzene/kg body wt."( Metabolism of [14C]benzene by cynomolgus monkeys and chimpanzees.
Birnbaum, LS; Couch, RC; Henderson, RF; Lefler, D; Lucier, G; Muggenburg, BA; Sabourin, PJ, 1992
)
0.28
" trans,trans-Muconic acid was identified and was unique to benzene as none was detected in urine of mice dosed orally with phenol, catechol or quinol (250, 150 and 200 mg/kg, respectively)."( trans,trans-Muconic acid, an open-chain urinary metabolite of benzene in mice. Quantification by high-pressure liquid chromatography.
Gad-El Karim, MM; Legator, MS; Ramanujam, VM, 1985
)
0.27
" This suggests that the dose-response curve is nonlinear; that potential different metabolic mechanisms exist at high and low doses; and that the validity of a linear extrapolation of adverse effects measured at high doses to a population exposed to lower, environmental levels of benzene is uncertain."( Biomarkers of environmental benzene exposure.
Georgopoulos, P; Roy, A; Weisel, C; Yu, R, 1996
)
0.29
" flavus dose-response curves to the tested antimicrobials with a highly satisfactory fit."( Aspergillus flavus dose-response curves to selected natural and synthetic antimicrobials.
Alzamora, SM; López-Malo, A; Palou, E, 2002
)
0.31
" These data demonstrate the dose-response relationship between SA administration and t,t-MA excretion."( Effect of sorbic acid administration on urinary trans,trans-muconic acid excretion in rats exposed to low levels of benzene.
Coccini, T; Maestri, L; Manzo, L; Marrubini, G, 2002
)
0.31
" It was concluded that under controlled study conditions: (1) 1-OHP, S-PMA and t,t-MA are useful biomarkers that could differentiate exposure between smoking conventional and EHCSS cigarettes or between smoking conventional cigarettes and no smoking; between S-PMA and t,t-MA, the former appeared to be more sensitive; (2) 3-MeAd could only differentiate between smoking conventional cigarettes and no smoking; the results for 3-EtAd were not conclusive because contradictory results were observed; (3) 8-OHdG had a questionable association with smoking and therefore the utility of this biomarker for smoking-related exposure could not be established; and (4) urinary excretion of thioethers as a biomarker lacked sensitivity to demonstrate a clear dose-response relationship in conventional cigarette smokers, although it could differentiate the excretion levels between those subjects who smoked a conventional cigarette and those who stopped smoking."( Evaluation of urinary 1-hydroxypyrene, S-phenylmercapturic acid, trans,trans-muconic acid, 3-methyladenine, 3-ethyladenine, 8-hydroxy-2'-deoxyguanosine and thioethers as biomarkers of exposure to cigarette smoke.
Engl, J; Feng, S; Jin, Y; Kinser, R; Liang, Q; Riedel, K; Roethig, HJ; Scherer, G; Urban, M,
)
0.13
" Anyway, in consideration of the carcinogenic properties of benzene and of its dose-response relation, without a treshold dose, we believe that the environmental and occupational monitoring is very important."( [Benzene low dose exposure: comparison of different biologic markers among exposed workers and the general population].
De Marchis, P; Picciotto, D; Schillaci, S; Tranchina, E; Tranchina, G; Verso, MG,
)
0.13
" Stratification shifted the dose-response curve to the right for benzalkonium chloride, thimerosal, chlorhexidine digluconate, potassium sorbate and EDTA."( Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells.
Evans, MG; Jessen, BA; Khoh-Reiter, S; Yanochko, GM, 2010
)
0.36
"Modern solid multiparticulate drug forms (minitablets, pellets, granules) can provide the possibility of precise dosing or modified drug release or taste masking for medicines used in children."( Application properties of oral gels as media for administration of minitablets and pellets to paediatric patients.
Kluk, A; Sznitowska, M, 2014
)
0.4
" amstelodami within the recommended dosage range for application in bakery products."( Antifungal properties of fermentates and their potential to replace sorbate and propionate in pound cake.
Devlieghere, F; Eeckhout, M; Samapundo, S; Vroman, A, 2016
)
0.43
"To investigate the changes in fermentation quality of whole-plant corn silage ensiled with varying dosages of mixed organic acid salts (MS), and link these dosage changes to shifts in bacterial composition."( A mixture of potassium sorbate and sodium benzoate improved fermentation quality of whole-plant corn silage by shifting bacterial communities.
Liu, Y; Meng, Q; Wu, H; Zhang, Y; Zhou, Z, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sorbic acidA hexadienoic acid with double bonds at C-2 and C-4; it has four geometrical isomers, of which the trans,trans-form is naturally occurring.
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency2.70560.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency11.23630.000221.22318,912.5098AID588516; AID743036; AID743040
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency42.56030.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency49.54240.000214.376460.0339AID588533; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.35770.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency46.30370.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency27.30600.001530.607315,848.9004AID1259401
aryl hydrocarbon receptorHomo sapiens (human)Potency27.30600.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency54.48270.001723.839378.1014AID743083
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.48720.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency0.18360.004611.374133.4983AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
Cellular tumor antigen p53Homo sapiens (human)Potency27.05630.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID309843Antimicrobial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2,4-hexadienoic acid derivatives.
AID1101859Antifungal activity against Saccharomyces cerevisiae ATCC 7754 at pH 5 after 48 hr by microdilution method2002Journal of agricultural and food chemistry, Jul-03, Volume: 50, Issue:14
Molecular design of antifungal agents.
AID1101856Antifungal activity against Saccharomyces cerevisiae ATCC 7754 at pH 3 after 48 hr by microdilution method2002Journal of agricultural and food chemistry, Jul-03, Volume: 50, Issue:14
Molecular design of antifungal agents.
AID1101860Antifungal activity against Saccharomyces cerevisiae ATCC 7754 at pH 7 after 48 hr by microdilution method2002Journal of agricultural and food chemistry, Jul-03, Volume: 50, Issue:14
Molecular design of antifungal agents.
AID1090229Antifungal activity against Zygosaccharomyces bailii assessed as growth inhibition measured after 48 hr by macrodilution assay2005Journal of agricultural and food chemistry, Jun-29, Volume: 53, Issue:13
Naturally occurring antifungal agents against Zygosaccharomyces bailii and their synergism.
AID309846Antifungal activity against Aspergillus niger after 7 days by twofold serial dilution method2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2,4-hexadienoic acid derivatives.
AID447578Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID309842Antimicrobial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2,4-hexadienoic acid derivatives.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1101861Antifungal activity against Saccharomyces cerevisiae ATCC 7754 at pH 9 after 48 hr by microdilution method2002Journal of agricultural and food chemistry, Jul-03, Volume: 50, Issue:14
Molecular design of antifungal agents.
AID1519394Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519399Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519396Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519398Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519392Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID309847Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2,4-hexadienoic acid derivatives.
AID1519393Antibacterial activity against Staphylococcus aureus ATCC 6538 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1519391Antibacterial activity against Staphylococcus aureus NCTC 4163 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID309844Antimicrobial activity against Escherichia coli after 24 hrs by twofold serial dilution method2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2,4-hexadienoic acid derivatives.
AID1519397Antibacterial activity against Escherichia coli NCTC 8196 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID309845Antifungal activity against Candida albicans after 2 days by twofold serial dilution method2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
Quantitative structure-activity relationship studies for prediction of antimicrobial activity of synthesized 2,4-hexadienoic acid derivatives.
AID1519395Antibacterial activity against Enterococcus hirae ATCC 10541 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID592088Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhage incubated with compound for 10 mins measured after 24 hrs2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Contribution of cinnamic acid analogues in rosmarinic acid to inhibition of snake venom induced hemorrhage.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,051)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990188 (17.89)18.7374
1990's170 (16.18)18.2507
2000's310 (29.50)29.6817
2010's306 (29.12)24.3611
2020's77 (7.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (1.15%)5.53%
Reviews29 (2.57%)6.00%
Case Studies17 (1.50%)4.05%
Observational0 (0.00%)0.25%
Other1,071 (94.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]